Evidence mapPaperPMID 33244652Full record

ArticleGeroScience2021

Towards resolving the enigma of the dichotomy of resveratrol: cis- and trans-resveratrol have opposite effects on TyrRS-regulated PARP1 activation.

Megha Jhanji, Chintada Nageswara Rao, Mathew Sajish

Open access · bronzeAbstract read
In one paragraph

Article in GeroScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Interaction between resveratrol and SIRT1: role in neurodegenerative diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  9. Article
  10. AKT-dependent nuclear localization of EPRS1 activates PARP1 in breast cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  11. Review
  12. Inhibition of ANO1 byInternational journal of molecular sciences · 2023
    Article
  13. Review
  14. Article
  15. Journal of medicine and life · 2022
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Megha JhanjiDepartment of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, 29208, USA.ORCID https://orcid.org/0000-0002-4796-8209
Chintada Nageswara RaoDepartment of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, 29208, USA.ORCID https://orcid.org/0000-0003-2451-0139
Mathew SajishDepartment of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, 29208, USA. mathew2@cop.sc.edu.ORCID https://orcid.org/0000-0001-6715-5953
University of South Carolina · US

Funding

NIGMS NIH HHS P20 GM109091
6 · The paper itself

Abstract

Unlike widely perceived, resveratrol (RSV) decreased the average lifespan and extended only the replicative lifespan in yeast. Similarly, although not widely discussed, RSV is also known to evoke neurite degeneration, kidney toxicity, atherosclerosis, premature senescence, and genotoxicity through yet unknown mechanisms. Nevertheless, in vivo animal models of diseases and human clinical trials demonstrate inconsistent protective and beneficial effects. Therefore, the mechanism of action of RSV that elicits beneficial effects remains an enigma. In a previously published work, we demonstrated structural similarities between RSV and tyrosine amino acid. RSV acts as a tyrosine antagonist and competes with it to bind to human tyrosyl-tRNA synthetase (TyrRS). Interestingly, although both isomers of RSV bind to TyrRS, only the cis-isomer evokes a unique structural change at the active site to promote its interaction with poly-ADP-ribose polymerase 1 (PARP1), a major determinant of cellular NAD

Indexed as

Tyrosine-tRNA LigaseAnimalsDNA DamageHumansPoly (ADP-Ribose) Polymerase-1ResveratrolPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1ResveratrolTyrosine-tRNA LigaseAminoacyl-tRNA synthetases (aaRSs)AMP-activated protein kinase (AMPK)Nicotinamide adenine nucleotide (NAD+)Nicotinamide (NAM)Poly-ADP-ribose polymerase (PARP)Resveratrol (RSV)Sirtuins (SIRT)Tyrosyl-tRNA synthetase (YARSTyrRS)

Identifiers

PMID33244652
PMCPMC7690980
OpenAlexW3107517055

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.